Kristie L. Kahl

Articles

Chemo-Free Combo Significantly Improves PFS in Previously Untreated CLL

June 4th 2019

The addition of venetoclax to obinutuzumab reduced the risk for disease worsening or death by 65% compared with obinutuzumab plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia.

Enfortumab Vedotin Produces Responses in Patients With Advanced Urothelial Carcinoma

June 3rd 2019

Enfortumab vedotin induced responses in 44% of patients with locally advanced or metastatic urothelial cancer, including 12% experiencing a complete response to treatment.

Maintenance Olaparib Improves PFS in BRCA+ Metastatic Pancreatic Cancer

June 2nd 2019

Maintenance therapy with olaparib significantly improved progression-free survival compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer.

Frontline Pembrolizumab Induces Comparable OS, Fewer AEs in Advanced GEJ Cancer

June 1st 2019

Frontline pembrolizumab demonstrated non-inferior overall survival compared with standard chemotherapy among patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.

Lenalidomide Reduces Risk for Smoldering Multiple Myeloma Progression

May 16th 2019

In patients with smoldering multiple myeloma, lenalidomide induced a 72% reduction in the risk for progression to symptomatic disease at 3 years.

Dostarlimab Yields Durable Response in MSI-H, MSS Endometrial Cancer

March 20th 2019

Patients with recurrent or advanced endometrial cancer demonstrated an overall response rate of almost 30% with dostarlimab treatment.

Olaparib Plus Neratinib Shows Early Potential in HER2+ Ovarian Cancer

March 19th 2019

Combination use of olaparib and neratinib may represent a novel therapeutic option for chemotherapy-resistant patients with HER2-positive, homologous recombination–proficient ovarian cancer tumors.

Neratinib Shows Promise in HER2-Mutant Cervical Cancer

March 19th 2019

Treatment with neratinib led to a clinical benefit rate of 54.5% in patients with HER2-mutant cervical cancer.

Pembrolizumab/Bevacizumab Regimen Induces Durable Responses in Ovarian Cancer

March 18th 2019

Combination therapy with pembrolizumab, bevacizumab, and metronomic cyclophosphamide induced a 95% disease control rate and 40% overall response rate among women with recurrent ovarian cancer.

Lenvatinib Combo Yields Favorable Responses in Ovarian, Endometrial Cancers

March 18th 2019

Lenvatinib in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, resulting in a 65% overall response rate.

Individualized Dosing Reduces Niraparib-Related TEAEs in Ovarian Cancer Maintenance

March 17th 2019

Adverse events decreased among patients with high-risk ovarian cancer who received a 200- or 300-mg individualized starting dose of niraparib, based upon baseline bodyweight and platelet count, compared with a 300-mg fixed starting dose.

Repeat Use of PARP Inhibitors Could Be Effective Strategy in Ovarian Cancer

March 17th 2019

Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, suggesting that repeat use could become more common.

Maintenance Niraparib Extends PFS Without Symptoms, Toxicities in Recurrent Ovarian Cancer

March 17th 2019

Patients with recurrent ovarian cancer who received niraparib maintenance therapy experienced more progression-free time without experiencing symptoms or toxicity compared with placebo; the benefit was 4-fold for those with germline (g) BRCA-mutated disease and 2-fold for non-gBRCA-mutated ovarian cancer.

Awareness Critical for Identifying irAEs Early in Breast Cancer

March 10th 2019

With tremendous advances and the accelerated approval of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer, provider education in identifying associated toxicities from checkpoint inhibitor therapy is critical.

Addition of Alpelisib Prolongs PFS in PIK3CA-Mutant HR+, HER2- Advanced Breast Cancer Subgroups

March 9th 2019

The previously demonstrated progression-free survival benefit from the addition of alpelisib to fulvestrant appeared consistent among subgroups of patients with hormone receptor–positive/HER2-negative advanced breast cancer who have a PIK3CA mutation.

Study Validates Speed, Accuracy of Liquid Biopsies Identifying NSCLC Biomarkers

February 28th 2019

A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non–small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.

Hormonal Agents Induce Improved OS in African Americans With Chemo-Naive mCRPC

February 12th 2019

African-American men with metastatic castration-resistant prostate cancer treated with novel hormonal therapies—namely abiraterone acetate or enzalutamide—lived 20% longer than their Caucasian counterparts.

FDA Delays Decision on Frontline Pembrolizumab sBLA in NSCLC

December 21st 2018

The FDA has extended the review period for a supplemental biologics license application for single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with a PD-L1 expression level of ≥1% and no EGFR or ALK genomic tumor aberrations.

Oxybutynin Decreases Hot Flashes, Improves Quality of Life in Breast Cancer Survivors

December 7th 2018

Oxybutynin helped to reduce the frequency and intensity of hot flashes among women who could not take hormone replacement therapy in survivorship.

Association Between pCR and Neoadjuvant Chemo Shows Improved Breast Cancer Outcomes

December 6th 2018

Pathologic complete response following neoadjuvant chemotherapy appeared to be associated with improved survival outcomes among patients with breast cancer.